Mr. Krauze is the founder, key shareholder and Chairman of the Polish biotechnological company Bioton SA – SciGen’s strategic investor since 2005. Today, Bioton leads a group of biotech and pharmaceutical companies operating in EU countries, Russia, China and Southeast Asia and is one of the world’s major manufacturer of recombinant human insulin. Since March 2005, Bioton is listed on the Warsaw Stock Exchange as part of the blue-chip WIG20 index. Bioton Group develops a portfolio of biotechnological products including among others human growth hormone sustained release. In June 2009, Bioton and SciGen have signed a 2 billion USD exclusive insulin supply and distribution agreement with Bayer Schering Pharma for the China market. Mr. Krauze was acting as the Vice-Chairman of the Board of Directors of SciGen from 2005 to 2008.

Mr. Krauze is also through his investment company, Prokom Investments, a key shareholder in two other companies floated on the Warsaw Stock Exchange and specialized in oil exploration and production (Petrolinvest Group) and real-estate development (Polnord Group).